206 related articles for article (PubMed ID: 11261808)
21. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection.
Akaike A; Takada-Takatori Y; Kume T; Izumi Y
J Mol Neurosci; 2010 Jan; 40(1-2):211-6. PubMed ID: 19714494
[TBL] [Abstract][Full Text] [Related]
22. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.
Lopes C; Pereira EF; Wu HQ; Purushottamachar P; Njar V; Schwarcz R; Albuquerque EX
J Pharmacol Exp Ther; 2007 Jul; 322(1):48-58. PubMed ID: 17446300
[TBL] [Abstract][Full Text] [Related]
23. Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine by low-dose galantamine in rats.
Hahn B; Reneski CH; Lane M; Elmer GI; Pereira EFR
Pharmacol Biochem Behav; 2020 Dec; 199():173043. PubMed ID: 33022302
[TBL] [Abstract][Full Text] [Related]
24. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
25. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons.
Fayuk D; Yakel JL
Mol Pharmacol; 2004 Sep; 66(3):658-66. PubMed ID: 15322258
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Caricati-Neto A; D'angelo LC; Reuter H; Hyppolito Jurkiewicz N; Garcia AG; Jurkiewicz A
Eur J Pharmacol; 2004 Oct; 503(1-3):191-201. PubMed ID: 15496314
[TBL] [Abstract][Full Text] [Related]
27. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Maelicke A
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
[TBL] [Abstract][Full Text] [Related]
28. [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].
Takatori Y
Yakugaku Zasshi; 2006 Aug; 126(8):607-16. PubMed ID: 16880719
[TBL] [Abstract][Full Text] [Related]
29. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
Nikiforuk A; Potasiewicz A; Kos T; Popik P
Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
[TBL] [Abstract][Full Text] [Related]
30. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning.
Woodruff-Pak DS; Vogel RW; Wenk GL
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):2089-94. PubMed ID: 11172080
[TBL] [Abstract][Full Text] [Related]
31. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
32. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505
[TBL] [Abstract][Full Text] [Related]
33. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Stahl SM
J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
[TBL] [Abstract][Full Text] [Related]
34. Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats.
Giarola A; Auber A; Chiamulera C
Behav Pharmacol; 2011 Feb; 22(1):1-6. PubMed ID: 21116174
[TBL] [Abstract][Full Text] [Related]
35. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.
Takada-Takatori Y; Kume T; Izumi Y; Ohgi Y; Niidome T; Fujii T; Sugimoto H; Akaike A
Biol Pharm Bull; 2009 Mar; 32(3):318-24. PubMed ID: 19252271
[TBL] [Abstract][Full Text] [Related]
36. Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells.
Barik J; Dajas-Bailador F; Wonnacott S
Br J Pharmacol; 2005 Aug; 145(8):1084-92. PubMed ID: 15937519
[TBL] [Abstract][Full Text] [Related]
37. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Maelicke A; Schrattenholz A; Samochocki M; Radina M; Albuquerque EX
Behav Brain Res; 2000 Aug; 113(1-2):199-206. PubMed ID: 10942046
[TBL] [Abstract][Full Text] [Related]
38. Galantamine: a review of its use in Alzheimer's disease.
Scott LJ; Goa KL
Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.
Kume T; Sugimoto M; Takada Y; Yamaguchi T; Yonezawa A; Katsuki H; Sugimoto H; Akaike A
Eur J Pharmacol; 2005 Dec; 527(1-3):77-85. PubMed ID: 16313899
[TBL] [Abstract][Full Text] [Related]
40. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
